Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $48.88 and last traded at $48.80, with a volume of 46,008 shares traded. The stock had previously closed at $48.38.
ENTA has been the subject of several research analyst reports. JMP Securities increased their target price on Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. BidaskClub upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Robert W. Baird increased their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 8th. Finally, Royal Bank Of Canada initiated coverage on Enanta Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating for the company. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $42.33.
The company’s 50-day moving average price is $44.76 and its 200 day moving average price is $36.71. The stock’s market capitalization is $939.32 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. The company had revenue of $7.51 million during the quarter, compared to analyst estimates of $8.08 million. During the same period in the previous year, the business earned ($0.06) EPS. Enanta Pharmaceuticals’s quarterly revenue was down 46.3% on a year-over-year basis. On average, equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post $1.14 EPS for the current year.
Large investors have recently bought and sold shares of the business. GAM Holding AG purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter worth approximately $108,000. Mason Street Advisors LLC increased its stake in Enanta Pharmaceuticals by 7.0% during the 1st quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in Enanta Pharmaceuticals by 3.5% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock worth $118,000 after buying an additional 110 shares in the last quarter. SG Americas Securities LLC increased its stake in Enanta Pharmaceuticals by 5.8% during the 2nd quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after buying an additional 237 shares in the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in Enanta Pharmaceuticals by 62.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock worth $159,000 after buying an additional 1,702 shares in the last quarter. Institutional investors own 66.06% of the company’s stock.
WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/2956286/enanta-pharmaceuticals-inc-enta-hits-new-12-month-high-at-48-88.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.